Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: A study in Belgian hospitals

Oncologist

Volumn 13, Issue 5, 2008, Pages 596-607

  Spaepen, Erik ^a   Demarteau, Nadia ^a   Van Belle, Simon ^b   Annemans, Lieven ^b  

^a IQVIA   (United States)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Anemia; Cancer; Chemotherapy; Economic; Erythropoiesis stimulating agents; Transfusion

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; BELGIUM; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEALTH CARE COSTS; HEMATINICS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 45749106812     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0219     Document Type: Article

References (48)

1. Harper P, Littlewood T. Anaemia of cancer: Impact on patient fatigue and long-term outcome. Oncology 2005;69(suppl 2):2-7.
2. Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
3. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
4. Lyman GH, Berndt ER, Kallich JD et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149-156.
5. Berndt E, Crown W, Kallich J et al. The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 2005;23:183-192.
6. Berndt E, Kallich J, McDermott A et al. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005;23:505-514.
7. Cella D, Kallich J, McDermott A et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomized clinical trials. Ann Oncol 2004;15:979-986.
8. Cremieux PY, Finkelstein SN, Berndt ER et al. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoeconomics 1999;16:459-472.
9. Kallich JD, Tchekmedyian NS, Damiano AM et al. Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology (Williston Park) 2002;16(suppl 10):117-124.
10. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
11. Ludwig H, Fritz E. Anemia of cancer patients: Patient selection and patient stratification for epoetin treatment. Semin Oncol 1998;25(suppl 7):35-38.
12. Van Bellinghen L, De Cock E. Comparing the provider time and costs for red blood cell transfusions in anemia management of cancer patients using the activity-based costing (ABC) method in a French and Austrian setting. Value Health 2003;6:735.
13. Regan F, Taylor C. Blood transfusion medicine. BMJ 2002;325:143-147.
14. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998;18:156-169.
15. Rizzo JD, Seidenfeld J, Piper M et al. Erythropoietin: A paradigm for the development of practice guidelines. Hematology Am Soc Hematol Educ Program 2001:10-30.
16. Mano M, Butzberger P, Reid A et al. Current role of erythropoietin in the management of patients with haematological and solid malignancy. Cancer Therapy 2003;3:41-56.
17. Egrie JC, Dwyer E, Browne JK et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-299.
18. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(suppl 1):3-10.
19. Glaspy J, Henry D, Patel R et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-1149.
20. Rearden T, Charu V, Saidman B et al. Results of a randomized study of every three-week dosing (Q3W) of darbepoetin alfa for chemotherapy-induced anaemia (CIA). Blood 2003;102:20b-21b.
21. Kotasek D, Steger G, Faught W et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-2034.
22. Canon JL, Vansteenkiste J, Bodoky G et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-284.
23. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
24. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
25. Marchetti M, Barosi G. Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 2004;22:1029-1045.
26. Stasi R, Amadori S, Littlewood TJ et al. Management of cancer-related anemia with erythropoietic agents: Doubts, certainties, and concerns. The Oncologist 2005;10:539-554.
27. Persson U, Borg S, Jansson S et al. Differences in treatment practice, response rates and cost of epoetin alfa and darbepoetin alfa treatment for anaemic cancer patients: A retrospective analysis from Sweden. Value Health 2004;7(suppl):681.
28. Reichardt B. Evidence-based, novel comparison between epoetin alfa, epoetin beta, and darbepoetin alfa based on drug use, efficacy and treatment costs in daily oncological clinical practice. Hematol J 2004;5(suppl 2):S177.
29. Reichardt B. Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting. J Clin Pharm Ther 2006;31:503-512.
30. Malonne H. Utilization and costs of epoetins and darbepoetin for treating platinum chemotherapy-induced anemia. J Clin Oncol 2005;23(16 suppl):6110.
31. Pujade-Lauraine E, Richard AJ, Sapède C et al. Erythropoietic agents in anaemic patients with cancer: A retrospective observational survey of epoetin alfa, epoetin beta and darbepoetin alfa use in routine clinical practice. Oncol Rep 2005;14:1037-1044.
32. National Center for Health Statistics. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available at http://www.cdc.gov/nchs/about/otheract/icd9/abticd9.htm. Accessed August 17, 2007.
33. Pirson M, Dramaix M, Leclercq P et al. Analysis of cost outliers within APR-DRGs in a Belgian general hospital: Two complementary approaches. Health Policy 2006;76:13-25.
34. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. Available at http://www.whocc.no/atcddd/. Accessed August 17, 2007.
35. Cellule Technique - Technical Cell of the Belgian Federal Ministry of Social Affairs, Public Health and Environment. Available at https://tct.fgov.be/ etct/index.html. Accessed August 17, 2007.
36. Statistics Belgium. Belgian Federal Public Service Economy, SMEs, Self-employed and Energy. Available at http://www.statbel.fgov.be/. Accessed August 17, 2007.
37. Closon M-C, Beguin C, Baele P et al. Etude d'une méthode de financement alternative pour le sang et les dérivés sanguins labiles dans les hôpitaux. KCE reports 12B. Brussels, Belgium: KCE, 2005:1-160.
38. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
39. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-524.
40. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
41. Parsons L. Reducing performing a 1:N case-control match on propensity score. Proceedings of the 29th Annual SAS Users Group International Conference. Cary, NC: SAS Institute, 2004;165-129.
42. Parsons L. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference. Cary, NC: SAS Institute, 2001;214-226.
43. Agresti A. Categorical Data Analysis, Second Edition. New York: Wiley, 2002:1-707.
44. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
45. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
46. Demarteau N, Moeremans K, Annemans L; ISPOR Task Force. Critical appraisal of scientific posters comparing anemia treatments for cancer patients: Applying ISPOR Task Force guidelines on methodological quality of retrospective studies. Crit Rev Oncol Hematol 2007;63:91-99.
47. Persson U, Borg S, Jansson S et al. Epoetin alfa and darbepoetin alfa for the treatment of chemotherapy-related anemia in cancer patients in Sweden: Comparative analysis of drug utilization, costs, and hematologic response. Adv Ther 2005;22:208-224.
48. Motheral B, Brooks J, Clark MA et al. A checklist for retrospective database studies: Report of the ISPOR Task Force on retrospective databases. Value Health 2003;6:90-97.